INSULET CORPORATION (NASDAQ:PODD) Files An 8-K Regulation FD Disclosure

INSULET CORPORATION (NASDAQ:PODD) Files An 8-K Regulation FD Disclosure
Item 7.01 – Regulation FD Disclosure.

Story continues below

On July 20, 2017, Insulet Corporation (the “Company”) issued a press release announcing the Company’s plans to assume, on July 1, 2018, the distribution, sales, marketing, training and support activities of Insulet’s Omnipod System across Europe following the expiration of the Company’s global distribution agreement with Ypsomed AG on June 30, 2018. A copy of that press release is furnished herewith as Exhibit 99.1 and attached hereto.

The information in this Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed “filed” for purposes of Section18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 7.01 – Financial Statements and Exhibits.


Exhibit Number



Press Release dated July 20, 2017.

EX-99.1 2 a51592753_ex991.htm EXHIBIT 99.1 Exhibit 99.1 Insulet to Assume Distribution and Commercial Support for Its Omnipod® System in Europe Direct Distribution Supports Strong and Growing European Customer Base Further Strengthens Company’s Financial Outlook BILLERICA,…
To view the full exhibit click here


Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The OmniPod System consists of the OmniPod, a small, self-adhesive disposable tubeless OmniPod device, which is worn on the body for approximately three days at a time and its wireless handheld Personal Diabetes Manager (PDM). The Company purchases OmniPods pursuant to its agreement with Flextronics. It also partners with pharmaceutical and biotechnology companies to tailor the OmniPod technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. It sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The Company purchases OmniPods pursuant to its agreement with Flextronics. The OmniPod System is available in Europe, Canada and Israel.

An ad to help with our costs